ACR Convergence 2023, the world’s premier rheumatology experience, was held Nov. 10–15 at the San Diego Convention Center. Attendees were inspired by lectures from Keynote speaker Avi Goldfarb, PhD, ARP Distinguished Lecturer Kaleb Michaud, PhD, and many, many more. Watch this page for complete coverage. Plus, explore our Psoriatic Arthritis and ANCA-Associated Vasculitis FocusRheums for research reviews, case reports and clinical articles on advances in the diagnosis and management of these conditions. And don’t forget to visit the ACR/ARP Abstracts website.
Explore our coverage of the top research in psoriatic arthritis and additional information presented at ACR Convergence 2023 and much more.
Review our collection of articles on anti-neutrophil cytoplasmic antibody-associated vasculitis, including information on GPA, MPA and EGPA.
Previous ACR Meetings
- ACR Convergence 2022
- ACR Convergence 2021
- ACR Convergence 2020
- 2019 ACR/ARP Annual Meeting
- 2018 ACR/ARHP Annual Meeting
- 2017 ACR/ARHP Annual Meeting
- 2016 ACR/ARHP Annual Meeting
- 2015 ACR/ARHP Annual Meeting
- 2014 ACR/ARHP Annual Meeting
- 2010 ACR/ARHP Annual Scientific Meeting
- 2009 ACR/ARHP Annual Scientific Meeting
- 2008 ACR/ARHP Annual Scientific Meeting
- 2006 ACR Annual Meeting
SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…
SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).
Expressing empathy, engaging patients in conversations about their emotional health and having an overall understanding of grief can help rheumatology health professionals better care for their patients. During a session at ACR Convergence 2023, mental health professionals and patients highlighted how grief affects patients with rheumatic disease and how providers can respond.
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
A panel of experts, including ACR on Air Host Jonathan Hausmann, MD, provided tips and insights into creating a podcast and engaging with an audience.
Researchers and physician-scientists often need practical advice for getting their work published. Here are insights into how to select an appropriate publication, manage co-author relationships and more from a panel of experts in both rheumatology and publishing.
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…